B+
Bull case
25%
Probability
Target price
$650.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
UTHR
United TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
UTHR has multiple potentially material cardiopulmonary expansion paths, including nebulized Tyvaso in IPF and ralinepag tablets in PAH, while Tyvaso DPI patient metrics remain strong. Stored earnings context also reported modest revenue and adjusted-EPS beats, though the source is secondary.
Posture
Constructive
Lead driver
Value
What changed
4 setup hits (3d) with net bullish as of 2026-10-27.
What can break
CEO Form 4 filings show multiple open-market sales on 2026-08-13 following an option exercise; this is insider-activity context, not evidence of operating performance [#SEC-FORM4-2026-08-14].
Momentum
95
Value
63
Sentiment
49
Setup hits (3d)
4 · Net Bullish
AI TargetsBase $540.00 · Bull $650.00 · Bear $425.00Analysis 2026-08-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $672.00
Why
Momentum95 · Δ7d +15.4
Value63 · Δ7d -0.7
Sentiment49 · Δ7d -10.4
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Confirming evidence
- • 4 setup hits (3d) with net bullish as of 2026-10-27.
- • Value remains the lead driver in the composite, 7D delta -0.7.
Contradictions & invalidation
- • CEO Form 4 filings show multiple open-market sales on 2026-08-13 following an option exercise; this is insider-activity context, not evidence of operating performance [#SEC-FORM4-2026-08-14].
- • Competitive pressure in inhaled prostacyclins could continue to offset Tyvaso DPI growth.
- • Near-term revenue and legacy-product declines indicate competitive and mix pressure.
Catalyst clock
2026-08-05
Mixed Q2 execution keeps near-term expectations restrained
Lead driver: Value · See fundamentals
Momentum
95
8% active weight
Current posture
7d trendImproving
Δ7d
+15.4
Δ21d
+36.5
Value
63
47% active weight
Current posture
7d trendFlat
Δ7d
-0.7
Δ21d
-1.0
Sentiment
49
45% active weight
Current posture
7d trendSoftening
Δ7d
-10.4
Δ21d
-19.4
Why this grade
Composite grade B. Momentum 94.8 / Value 63.4 / Sentiment 49.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-17. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$540.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$425.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$25.36B
Beta
0.86
Shares Out
42.89M
P/E (TTM)
18.5
P/S (TTM)
6.74
P/FCF (TTM)
18.89
Rev YoY
-1.9%
EPS YoY
+13.5%
Gross Margin
+86.1%
Op Margin
+44.5%
Net Debt
-$2.92B
Current Ratio
5.73
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data